Positive data for Zafgen's obesity candidate give indication a boost
This article was originally published in Scrip
Zafgen, a biopharmaceutical firm based in Cambridge, Massachusetts, US, says its lead compound, ZGN-433, for severely obese patients, has met both its primary and secondary endpoints in a Phase Ib trial. The level of weight loss observed was close to the levels that are only exceeded by surgical intervention, according to the company.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.